BioSpace

Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca

AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.

By BioSpace

1 min read
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights